



InoRx

Simplifying Trials. Accelerating Cures.



FACT SHEET

Why InoRx for Oncology

Overview

InoRx enables oncology clinical trials in India through a high-density, regulatory-ready network of leading cancer centers. By integrating government, academic, and private oncology institutions, InoRx provides access to diverse patient populations, experienced investigators, and scalable infrastructure across Phase I-IV studies.

Recruitment Model Advantage

InoRx delivers a differentiated recruitment model designed for both speed and depth:


- Apex centers contribute high patient volumes, including ~70,000 new patients annually and ~400,000+ follow-ups
- Mid-tier sites contribute approximately 25,000-30,000 patients annually per site

This blended model enables:

- Predictable recruitment
- Accelerated enrollment timelines
- Broad access across indications

Why Sponsors Choose InoRx

- Accelerated recruitment through a high-density, multi-site oncology network
- Access to diverse patient populations across major tumor types and geographies
- Execution by experienced investigators in premiere oncology centers
- Consistent quality and regulatory alignment across Phase I-IV studies



Clinical Trial Experience

- Phase I-IV oncology trials
- Advanced and metastatic disease studies
- Early-phase PK/PD capability at select sites
- Experience supporting multi-line therapy protocols

Operational Model

- Central feasibility and site selection
- Parallel site activation to accelerate timelines
- Continuous oversight ensuring quality, compliance, and data integrity

Regulatory Experience

Experience supporting global trials and submissions to:

- U.S. Food and Drug Administration (FDA)
- European Medicines Agency (EMA)
- Central Drugs Standard Control Organization (CDSCO)

Sites operate in compliance with ICH-GCP and are experienced in audits and inspections.

Integrated Oncology Ecosystem


- Diagnostics, surgery, chemotherapy, and radiotherapy access
- Inpatient and outpatient oncology care
- Cross-referral practices supporting patient identification and recruitment
- Multicenter and investigator-initiated study capabilities

Investigator and Site Strength

- Multi-indication investigator expertise across major tumor types

Oncology Indication Coverage

% of sites with oncology experience by indication:



Coverage reflects the percentage of network sites with clinical experience by indication.

- Strong KOL-driven ecosystem supporting protocol adherence
- Experience managing complex oncology protocols
- Operationally efficient clinical teams with strong compliance practices

Value Delivered to Sponsors

- Accelerated patient recruitment
- Scalable, pan-India oncology site network
- Consistent quality and regulatory compliance
- Access to high-volume centers and experienced investigators
- Reliable execution across Phase I-IV oncology trials

About InoRx

InoRx is a next-generation Contract Research Organization (CRO) accelerating clinical development through innovation, patient access, and operational excellence. Backed by the SRM Group, a \$1.4 billion global enterprise, InoRx delivers faster, more reliable, and cost-effective clinical research for biotech and pharma sponsors worldwide. Discover more at InoRx.com, follow on LinkedIn, and Email hello@InoRx.com.